Physician profile
Winston H Griner
NPI 1922136449
$4,344.33
in general payments reported to CMS, 2019-2025
12 companies · $2,133 in 2025
The $2,133 reported for 2025 was more than what 93% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.98 · 2023: $950 · 2024: $1,249 · 2025: $2,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,332.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $844.88 | 2023-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $590.84 | 2023-2025 | Caplyta |
| Alkermes, INC. | $585.56 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $582.34 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $463.73 | 2023-2025 | Auvelity |
| Abbvie INC. | $341.89 | 2024-2025 | |
| Braeburn INC. | $325.48 | 2024-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $240.63 | 2025 | Cobenfy |
| Indivior INC. | $122.34 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $119.26 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $115.40 | 2023 | Rexulti |
| Gilead Sciences, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winston Griner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.